We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Wyeth Pharmaceuticals has received FDA approval for Tygacil, an intravenous
antibiotic intended to treat skin and soft tissue infections, such as those
caused by burns, appendicitis, abscesses and ulcers.
Myriad Genetics announced that results of its Phase II clinical trial of Flurizan
in patients with mild-to-moderate Alzheimer's disease will be presented as part
of the Alzheimer's Association International Conference on Prevention of Dementia,
in Washington, D.C.
CytRx (RNAi) has submitted a reply to a request for additional information from
the FDA related to the company's investigational new drug (IND) application
for arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS or Lou
Gehrig's disease).
ZymoGenetics has announced highlights from a presentation given by clinical
investigator Jeffrey Lawson, M.D. of Duke University Medical Center at the spring
meeting of the Peripheral Vascular Surgery Society in Chicago.
Adventrx Pharmaceuticals has announced response data from all 48 measurable
patients in its 50-patient Phase II trial with CoFactor and 5-fluorouracil (5-FU)
as a first-line treatment for metastatic colorectal cancer.
Durect has announced positive preliminary results from the second cohort of
an on-going Phase II clinical study in hernia patients for Durect's postoperative
pain relief depot product candidate, SABER-Bupivacaine.
Transkaryotic Therapies has announced positive top-line results from the company's
pivotal Phase III clinical trial evaluating its investigational human enzyme
replacement therapy, iduronate-2-sulfatase (I2S), for the treatment of patients
with Hunter syndrome.
Alnylam Pharmaceuticals has received a notice of grant from the European Patent Office for an important new RNAi patent titled, "Inhibiting gene expression with double-stranded RNA," to which Alnylam has exclusive therapeutic rights, through its existing license agreement with CRT.
Immunomedics has received notices that the U.S. and Australian patent offices have allowed claims in respective patent applications covering methods for treating a wide range of autoimmune diseases using monoclonal antibodies that bind to the CD22 antigen present on B-lymphocytes.
Vical has announced the receipt of approximately $12.1 million in production orders for multiple clinical lots of DNA vaccines against HIV for the Vaccine Research Center (VRC) at the NIH's National Institute of Allergy and Infectious Diseases, under a subcontract managed by SAIC-Frederick.